Showing 7431-7440 of 8825 results for "".
- Incyte Scores Vitiligo Nod for Opzelura Cream in Europehttps://practicaldermatology.com/news/incyte-scores-nod-for-opzelura-cream-for-vitiligo-in-europe/2461674/The European Commission (EC) has granted a marketing authorization for Opzelura (ruxolitinib) cream15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The selective JAK1/JAK2 inhibi
- Galderma Survey Debunks Filler Mythshttps://practicaldermatology.com/news/galderma-survey-debunks-filler-myths/2461668/Forty percent of people say they would discourage others from using facial injectables to reduce wrinkles or provide volume, and 34% said they believed the results of such treatments look fake and unnatural, according to a new poll sponsored by Galderma. Despite these views, the same re
- 2023 Medscape Report: Physician Salaries Rise as Gender Gap Narrowshttps://practicaldermatology.com/news/2023-medscape-report-physician-salaries-rise-as-gender-gap-narrows/2461663/Doctor salaries continue to rise as the gender gap narrows, according to the 2023 Medscape Physician Compensation Report. The largest difference for women was seen in primary care, but the disparity also narrowed within specialties, from a 36% difference i
- Adding New Personalized Vaccine to Immunotherapy Slashes Risk for Melanoma Recurrencehttps://practicaldermatology.com/news/adding-new-personalized-vaccine-to-immunotherapy-slashes-risk-for-melanoma-recurrence/2461662/Adding an experimental mRNA vaccine to immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when compared with immunotherapy alone, a new clinical trial shows. The phase 2b trial results were presented at the annual meeting of the American A
- FDA Clears New Underarm Sweat Control Patchhttps://practicaldermatology.com/news/fda-clears-new-underarm-sweat-control-patch/2461660/The U.S. Food and Drug Administration (FDA) has cleared cleared Brella, the first 3-Minute SweatControl Patch to significantly reduce excessive underarm sweating in adults with primary axillary hyperhidrosis. The Brella SweatControl Patch provide
- Eczema Breakthrough: S. aureus Evolve to a Variant with a Mutation in a Specific Gene to Grow Fasterhttps://practicaldermatology.com/news/eczema-breakthrough-s-aureus-evolve-to-a-variant-with-a-mutation-in-a-specific-gene-to-grow-faster/2461659/New research shows how Staphylococcus aureus gains mutations that allow it to colonize eczema patches. In people with eczema, S. aureus tends to evolve to a variant with a mutation in a specific gene that helps it grow faster on the skin. This study marks the first t
- Prior Immunotherapy May Predict Response to PD-1 Checkpoint Blockadehttps://practicaldermatology.com/news/prior-immunotherapy-may-predict-response-to-pd-1-checkpoint-blockade/2461655/Responses to PD-1 checkpoint blockade in patients with advanced melanoma depend on whether or not they had previously received CTLA-4 blockade as well as other factors, new research suggests. Their findings, based on analysis of seven data sets generated over the past decade, which incl
- Cutera CEO, Executive Chairman Axedhttps://practicaldermatology.com/news/shake-up-at-cutera-shareholder-ceo-look-to-reconstitute-board/2461654/Cutera, Inc. has fired CEO David Mowry and Executive Chairman Daniel Plants for alleged violations of their employment contracts. Sheila Hopkins has been appointed as interim CEO and the search for a permanent replacement is underway. Plants and Mowry called for a Sp
- Dr. Susan C. Taylor Elected 2025 AAD Presidenthttps://practicaldermatology.com/news/dr-susan-c-taylor-elected-2025-aad-president/2461653/Susan C. Taylor, MD, FAAD is the American Academy of Dermatology’s president-elect. She will be installed in March 2024 and hold the office of president for one year beginning in March 2025. Dr. Taylor previously served as AAD Vice President from 2020 – 2021.
- News You Can Use: BI Receives Permanent J-Code (J1747) for SPEVIGO Injectionhttps://practicaldermatology.com/news/news-you-can-use-bi-receives-permanent-j-code-j1747-for-spevigo-injection/2461649/The U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-code (J1747) for Boehringer Ingelheim’s SPEVIGO (spesolimab-sbzo) Injection, indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults. The J-code for SPEVIGO became eff